Rosuvastatin
Clinical Trials Overview
2 trials found
About Rosuvastatin
Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) primarily used to lower cholesterol and prevent cardiovascular disease. In colorectal cancer treatment, rosuvastatin is being evaluated for its potential anti-cancer properties based on preclinical evidence that statins may inhibit tumor growth and metastasis. Clinical trials are examining whether rosuvastatin can improve outcomes when added to standard CRC treatment, particularly in patients with early-stage surgically resected colon cancer.
Category
Other Medications
Brand Name
Crestor, Ezallor Sprinkle
Mechanism
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, blocking the conversion of HMG-CoA to mevalonate. Beyond cholesterol reduction, this inhibition disrupts the mevalonate pathway, which affects prenylation of proteins involved in cell proliferation, apoptosis, and angiogenesis. The anti-cancer effects may result from reduced protein prenylation affecting oncogenic signaling pathways including Ras and Rho family proteins.
2
Total Trials
0
Recruiting
0
Active
2
Completed
438
Total Enrollment
2
Countries
Phase:
NCT05368805
Phase 1
Completed
32 patients
Medications:
Fruquintinib
Rosuvastatin
Fruquintinib DDI Study with P-gp and BCRP Substrates
United States
NCT01011478
Phase 3
Completed
406 patients
Medications:
Rosuvastatin
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon can...
United States, Canada